Clinical performance is complex and often involves multi-systematic stress. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnostic and treatment plans. Treatment and management of the treatment plans associated with CK syndrome require individual development, usually including pharmacotherapy, rehabilitation interventions, regular follow-up, etc. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in conditions. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the elevation of CK associated with synthetase syndrome. The platform serves China International Medical Service System, a team of domestically authoritative experts in the field of autoimmune and rheumatic immunity, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of changes in conditions and treatment effects.